Fox Run Management’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Fox Run Management’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-28,700	Closed	-$321K	–	1009
2017 Q3	$321K	Buy	+28,700	New	+$317K	0.09%	460
2016 Q4	–	Sell	-22,400	Closed	-$230K	–	779
2016 Q3	$230K	Buy	22,400 +8,600	+62%	+$93.7K	0.14%	362
2016 Q2	$180K	Buy	+13,800	New	+$181K	0.09%	458

Fox Run Management's SCLN Position: Q4 2017 in Review

Fox Run Management sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 28,700 shares — an estimated $321K sold.

Fox Run Management first reported a position in SCLN in Q2 2016 and held it in 3 quarters. The position peaked at $321K in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.

Fox Run Management reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
Fox Run Management sold 28,700 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $321K.
Fox Run Management first reported a position in Sciclone Pharmaceuticals Inc in Q2 2016 and held it in 3 quarters.
Fox Run Management's Sciclone Pharmaceuticals Inc position peaked at $321K in Q3 2017.
0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.

Based on Fox Run Management's 13F filing for Q4 2017, filed 18 Jan 2018.